These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24845945)

  • 41. Drug-induced long QT syndrome: Concept and non-clinical models for predicting the onset of drug-induced torsade de pointes in patients in compliance with ICH E14/S7B guidance.
    Sugiyama A; Goto A; Izumi-Nakaseko H; Takei Y; Takahara A; Kambayashi R
    J Pharmacol Exp Ther; 2024 Aug; ():. PubMed ID: 39168651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
    Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization.
    Guth BD; Germeyer S; Kolb W; Markert M
    J Pharmacol Toxicol Methods; 2004; 49(3):159-69. PubMed ID: 15172012
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging.
    Dempsey GT; Chaudhary KW; Atwater N; Nguyen C; Brown BS; McNeish JD; Cohen AE; Kralj JM
    J Pharmacol Toxicol Methods; 2016; 81():240-50. PubMed ID: 27184445
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery.
    Gintant G; Fermini B; Stockbridge N; Strauss D
    Cell Stem Cell; 2017 Jul; 21(1):14-17. PubMed ID: 28686863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early afterdepolarizations in cardiac action potentials as mixed mode oscillations due to a folded node singularity.
    Kügler P; Erhardt AH; Bulelzai MAK
    PLoS One; 2018; 13(12):e0209498. PubMed ID: 30596698
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of study design on proarrhythmia prediction in the SCREENIT rabbit isolated heart model.
    Steidl-Nichols JV; Hanton G; Leaney J; Liu RC; Leishman D; McHarg A; Wallis R
    J Pharmacol Toxicol Methods; 2008; 57(1):9-22. PubMed ID: 17707659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent developments in the science of proarrhythmic cardiac safety of new drugs.
    Turner JR; Karnad DR; Cabell CH; Kothari S
    Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):118-124. PubMed ID: 28363206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety pharmacology in 2022: Taking one small step for cardiovascular safety assay development but one giant leap for regulatory drug safety assessment.
    Pugsley MK; Koshman YE; de Korte T; Authier S; Winters BR; Curtis MJ
    J Pharmacol Toxicol Methods; 2022; 117():107206. PubMed ID: 35926772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept.
    Abbasi M; Small BG; Patel N; Jamei M; Polak S
    Toxicol Mech Methods; 2017 Feb; 27(2):88-99. PubMed ID: 27813448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Points to consider for a validation study of iPS cell-derived cardiomyocytes using a multi-electrode array system.
    Kanda Y; Yamazaki D; Kurokawa J; Inutsuka T; Sekino Y
    J Pharmacol Toxicol Methods; 2016; 81():196-200. PubMed ID: 27369811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug potency on inhibiting late Na
    Wu M; Tran PN; Sheng J; Randolph AL; Wu WW
    J Pharmacol Toxicol Methods; 2019; 100():106605. PubMed ID: 31255744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Cardiovascular safety pharmacology: in vitro strategies and improvements in technology and evaluation].
    Yoshinaga T
    Nihon Yakurigaku Zasshi; 2021; 156(5):297-302. PubMed ID: 34470935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent developments in using mechanistic cardiac modelling for drug safety evaluation.
    Davies MR; Wang K; Mirams GR; Caruso A; Noble D; Walz A; Lavé T; Schuler F; Singer T; Polonchuk L
    Drug Discov Today; 2016 Jun; 21(6):924-38. PubMed ID: 26891981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interpretation of field potentials measured on a multi electrode array in pharmacological toxicity screening on primary and human pluripotent stem cell-derived cardiomyocytes.
    Tertoolen LGJ; Braam SR; van Meer BJ; Passier R; Mummery CL
    Biochem Biophys Res Commun; 2018 Mar; 497(4):1135-1141. PubMed ID: 28153730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive
    Yoon SH; Lee HL; Jeong DU; Lim KM; Park SJ; Kim KS
    Front Pharmacol; 2023; 14():1220796. PubMed ID: 37649890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Innovative approaches to cardiovascular safety pharmacology assessment.
    Pugsley MK; Winters BR; Koshman YE; Authier S; Foley CM; Hayes ES; Curtis MJ
    J Pharmacol Toxicol Methods; 2024; 128():107533. PubMed ID: 38945308
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System.
    Xi B; Wang T; Li N; Ouyang W; Zhang W; Wu J; Xu X; Wang X; Abassi YA
    J Lab Autom; 2011 Dec; 16(6):415-21. PubMed ID: 22093298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Computational modeling for cardiac safety pharmacology analysis: Contribution of fibroblasts.
    Gao X; Engel T; Carlson BE; Wakatsuki T
    J Pharmacol Toxicol Methods; 2017 Sep; 87():68-73. PubMed ID: 28456609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.